Evaluation of an Intranasal Virosomal Vaccine against Respiratory Syncytial Virus in Mice: Effect of TLR2 and NOD2 Ligands on Induction of Systemic and Mucosal Immune Responses

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Shafique, Muhammad ^a   Meijerhof, Tjarko ^a   Wilschut, Jan ^a   de Haan, Aalzen ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 5; MURAMYL DIPEPTIDE; N PAMITOYL[2,3 BIS(PALMITOYLOXY)PROPYL]CYSTEINYLSERYLLYSYL 3 LYSINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG; VIROSOME VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ARTICLE; CELL LINE; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PROTEIN INDUCTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION;

ADMINISTRATION, INTRANASAL; ANIMALS; CELL LINE; FEMALE; HUMANS; IMMUNITY, MUCOSAL; LIGANDS; LUNG; MICE; NOD2 SIGNALING ADAPTOR PROTEIN; RESPIRATORY SYNCYTIAL VIRUSES; SPECIES SPECIFICITY; TOLL-LIKE RECEPTOR 2; VACCINES, VIROSOME;

MURINAE; MUS; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

EID: 84876006537     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061287     Document Type: Article

References (42)

1. van Drunen Littel-van den Hurk S, Mapletoft JW, Arsic N, Kovacs-Nolan J, (2007) Immunopathology of RSV infection: prospects for developing vaccines without this complication. Rev Med Virol 17: 5-34.
2. Dowell SF, Anderson LJ, Gary HE, Erdman DD, Plouffe JF, et al. (1996) Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J Infect Dis 174: 456-462.
3. Hall CB, Walsh EE, Long CE, Schnabel KC, (1991) Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 163: 693-698.
4. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, et al. (1969) Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89: 422-434.
5. Waris ME, Tsou C, Erdman DD, Zaki SR, Anderson LJ, (1996) Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 70: 2852-2860.
6. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, et al. (2009) Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 15: 34-41.
7. Johnson TR, Rao S, Seder RA, Chen M, Graham BS, (2009) TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity. Vaccine 27: 3045-3052.
8. Shafique M, Wilschut J, de Haan A, (2012) Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands. Vaccine 30: 597-606.
9. Hussell T, Humphreys IR, (2002) Nasal vaccination induces protective immunity without immunopathology. Clin Exp Immunol 130: 359-362.
10. Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, et al. (2005) The virosome concept for influenza vaccines. Vaccine 23: S26-38.
11. Stegmann T, Kamphuis T, Meijerhof T, Goud E, de Haan A, et al. (2010) Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation. Vaccine 28: 5543-5550.
12. Kamphuis T, Meijerhof T, Stegmann T, Lederhofer J, Wilschut J, et al. (2012) Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice. PLoS One 7: e36812.
13. Lawson LB, Norton EB, Clements JD, (2013) Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Curr Opin Immunol 23: 414-420.
14. De Jonge J, Leenhouts JM, Holtrop M, Schoen P, Scherrer P, et al. (2007) Cellular gene transfer mediated by influenza virosomes with encapsulated plasmid DNA. Biochem J 405: 41-49.
15. Parker D, Prince A, (2011) Innate immunity in the respiratory epithelium. Am J Respir Cell Mol Biol 45: 189-201.
16. Borsutzky S, Kretschmer K, Becker PD, Muhlradt PF, Kirschning CJ, et al. (2005) The mucosal adjuvant macrophage-activating lipopeptide-2 directly stimulates B lymphocytes via the TLR2 without the need of accessory cells. J Immunol 174: 6308-6313.
17. Ainai A, Ichinohe T, Tamura S, Kurata T, Sata T, et al. (2010) Zymosan enhances the mucosal adjuvant activity of poly(I:C) in a nasal influenza vaccine. J Med Virol 82: 476-484.
18. Liang Y, Hasturk H, Elliot J, Noronha A, Liu X, et al. (2011) Toll-like receptor 2 induces mucosal homing receptor expression and IgA production by human B cells. Clin Immunol 138: 33-40.
19. Fukushima A, Yoo YC, Yoshimatsu K, Matsuzawa K, Tamura M, et al. (1996) Effect of MDP-Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus. Vaccine 14: 485-491.
20. Ogawa T, Shimauchi H, Hamada S, (1989) Mucosal and systemic immune responses in BALB/c mice to Bacteroides gingivalis fimbriae administered orally. Infect Immun 57: 3466-71.
21. Tada H, Aiba S, Shibata K, Ohteki T, Takada H, (2005) Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells. Infect Immun 73: 7967-7976.
22. Uehara A, Yang S, Fujimoto Y, Fukase K, Kusumoto S, et al. (2005) Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocytic cells in culture. Cell Microbiol 7: 53-61.
23. Petterson T, Jendholm J, Mansson A, Bjartell A, Riesbeck K, et al. (2011) Effects of NOD-like receptors in human B lymphocytes and crosstalk between NOD1/NOD2 and Toll-like receptors. J Leukoc Biol 89: 177-187.
24. Prince GA, Denamur F, Deschamps M, Garcon N, Prieels JP, et al. (2001) Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease. Vaccine 19: 2048-2054.
25. De Haan A, Geerligs HJ, Huchshorn JP, Van Scharrenburg GJ, Palache AM, et al. (1995) Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes. Vaccine 13: 155-162.
26. Ogra PL, Faden H, Welliver RC, (2001) Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 14: 430-445.
27. Baca-Estrada ME, Foldvari M, Babiuk SL, Babiuk LA, (2000) Vaccine delivery: lipid-based delivery systems. J Biotechnol 83: 91-104.
28. Holmgren J, Lycke N, Czerkinsky C, (1993) Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine 11: 1179-1184.
29. Yamamoto S, Takeda Y, Yamamoto M, Kurazono H, Imaoka K, et al. (1997) Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J Exp Med 185: 1203-1210.
30. Roberts M, Bacon A, Rappuoli R, Pizza M, Cropley I, et al. (1995) A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins. Infect Immun 63: 2100-2108.
31. Hennessy EJ, Parker AE, O'Neill LA, (2010) Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 9: 293-307.
32. Caproni E, Tritto E, Cortese M, Muzzi A, Mosca F, et al. (2012) MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action. J Immunol 188: 3088-3098.
33. Nguyen DT, De Witte L, Ludlow M, Yuksel S, Wiesmuller KH, et al. (2010) The synthetic bacterial lipopeptide Pam3CSK4 modulates respiratory syncytial virus infection independent of TLR activation. PLoS Pathog 6: e1001049.
34. Cashman SB, Morgan JG, (2009) Transcriptional analysis of Toll-like receptors expression in M cells. Mol Immunol 47: 365-372.
35. Chabot SM, Chernin TS, Shawi M, Wagner J, Farrant S, et al. (2007) TLR2 activation by proteosomes promotes uptake of particulate vaccines at mucosal surfaces. Vaccine 25: 5348-5358.
36. Magalhaes JG, Fritz JH, Le Bourhis L, Sellge G, Travassos LH, et al. (2008) Nod2-dependent Th2 polarization of antigen-specific immunity. J Immunol 181: 7925-7935.
37. Auci DL, Kleiner GI, Chice SM, Athanassiades TJ, Dukor P, et al. (1998) Control of IgE responses. V. Oral administration of a synthetic derivative of the inner bacterial cell wall (SDZ 280.636) to sensitized mice induces isotype specific suppression of peak hapten specific IgE antibody forming cell responses, serum IgE levels and immediate hypersensitivity responses. Immunol Invest 27: 105-120.
38. Renegar KB, Small PA Jr, Boykins LG, Wright PF, (2004) Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 173: 1978-1986.
39. Walsh EE, Falsey AR, (2004) Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis 190: 373-378.
40. Walsh EE, Peterson DR, Falsey AR, (2004) Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis 189: 233-238.
41. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, et al. (2000) Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 1: 398-401.
42. Murawski MR, Bowen GN. Cerny AM, Anderson LJ, Haynes LM, et al. (2009) Respiratory Syncytial Virus Activates Innate Immunity through Toll-Like Receptor 2. J Virol 83: 1492-1500.